Results 31 to 40 of about 75,353,973 (171)

Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population [PDF]

Ophthalmology and Therapy
Introduction Recent advances in the development of antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD) include the approval of aflibercept 8 mg, which delivers four times the previously ...
Chui Ming Gemmy Cheung, Wataru Kikushima, Kelvin Y. C. Teo   +2 more
doaj   +2 more sources

Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series

BMJ Open Ophthalmology
Objective This real-world retrospective case series evaluates the safety and efficacy of aflibercept 8 mg in patients diagnosed with neovascular age-related macular degeneration (nAMD).Methods and analyses Treatment-naïve or treatment-experienced ...
David A Eichenbaum, Deepak Sambhara, Priya Vakharia   +2 more
doaj   +3 more sources

Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification

Ophthalmology and Therapy
Introduction To evaluate the early outcomes of aflibercept 8 mg (afl8) treatment in patients with neovascular age-related macular degeneration (nAMD) previously treated with aflibercept 2 mg (afl2).
Nicolò Bartolomeo, Konstantinos Kitsos Kalyvianakis, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat, Mamadou Pathé Barry, Aude Ambresin   +7 more
doaj   +4 more sources

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom [PDF]

Life
(1) Aim: To evaluate early real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom. (2) Methods: This retrospective, observational study included 59 eyes from 50 patients
Muiz Musadiq, Mohammed Musadiq, Fozia Latif, Benjamin Ng, Matthew Azzopardi, Noa Gilead, Andrew Needham, Yu Jeat Chong   +7 more
doaj   +2 more sources

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases [PDF]

International Medical Case Reports Journal
Ikumi Kashiwagi, Ryota Nonaka, Shotaro Sasaki, Takuto Yamamoto, Kanako Yasuda, Masahiko Shimura Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, JapanCorrespondence: Masahiko Shimura, Department of ...
Kashiwagi I, Nonaka R, Sasaki S, Yamamoto T, Yasuda K, Shimura M   +5 more
doaj   +1 more source

Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden [PDF]

Ophthalmology and Therapy
Introduction This study aimed to evaluate functional, anatomical, and safety outcomes after switching from aflibercept 2 mg to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) requiring short re-treatment intervals in
Christoph Spartalis, Marlies Ullrich, Silvia Winkler, Christoph Leisser, Manuel Ruiss, Caroline Pilwachs, Oliver Findl   +6 more
doaj   +2 more sources

Short-term intraocular pressure changes following intravitreal aflibercept 8 mg versus 2 mg in diabetic macular edema: a prospective observational study [PDF]

Scientific Reports
This prospective observational study evaluated short-term intraocular pressure (IOP) changes and safety following intravitreal injection of aflibercept 8 mg versus 2 mg in diabetic macular edema (DME).
Ken Hoshiyama, Takao Hirano, Erika Sekiya, Shingo Kajiwara, Shuji Mukawa, Yoshiaki Chiku, Marie Nakamura, Noriko Yoshida, Toshinori Murata   +8 more
doaj   +2 more sources

Early intraocular pressure kinetics after intravitreal aflibercept 8 mg (0.07 mL) versus aflibercept 2 mg (0.05 mL) in nonglaucomatous eyes: a prospective comparative study [PDF]

International Journal of Retina and Vitreous
Background Transient intraocular pressure (IOP) spikes after intravitreal injection (IVI) are expected. The higher-volume aflibercept 8 mg (0.07 mL) formulation has recently entered clinical use, yet its early IOP kinetics—particularly the immediate post-
Annika Licht, Astrid Schneider, V. Romanou, Alireza Mirshahi   +3 more
doaj   +2 more sources

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis [PDF]

Ophthalmology and Therapy
Introduction Aflibercept 8 mg administered in extended dosing intervals has shown non-inferior visual gains and comparable safety profile to aflibercept 2 mg in the PULSAR pivotal randomized clinical trial and has the potential to reduce the treatment ...
Piotr Wojciechowski, Marlena Wdowiak, Malgorzata Panek, Izabella Lunk, Joao Carrasco, Xin Zhang, Olivia Wu, Jean-François Korobelnik, Paolo Lanzetta   +8 more
doaj   +2 more sources

Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema

AJO International
Objective: To evaluate and compare the effectiveness and treatment burden of faricimab and aflibercept 8 mg in treatment-naive patients with diabetic macular edema (DME) using a pro re nata (PRN) protocol.
Carlo Maccauro, Yanny Jimenez Perez, Piergiorgio Neri, Ibraheem El Ghrably, Haytham I Salti, Francesco Pichi   +5 more
doaj   +2 more sources